Serial positron-emission tomography after induction therapy as a predictor of prognostic outcomes for patients with thymic carcinoma.

IF 1.7 4区医学 Q2 SURGERY Surgery Today Pub Date : 2024-12-05 DOI:10.1007/s00595-024-02954-3

Yudai Miyashita, Takashi Kanou, Tomomi Isono, Hiroto Ishida, Hideki Nagata, Teiko Sakurai, Kenji Kimura, Eriko Fukui, Toru Kimura, Naoko Ose, Tadashi Watabe, Yasushi Shintani

{"title":"Serial positron-emission tomography after induction therapy as a predictor of prognostic outcomes for patients with thymic carcinoma.","authors":"Yudai Miyashita, Takashi Kanou, Tomomi Isono, Hiroto Ishida, Hideki Nagata, Teiko Sakurai, Kenji Kimura, Eriko Fukui, Toru Kimura, Naoko Ose, Tadashi Watabe, Yasushi Shintani","doi":"10.1007/s00595-024-02954-3","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate the role of 18F-fluorodeoxy glucose-positron emission tomography/computed tomography (FDG-PET/CT) to assess pathological response and prognosis after induction therapy in patients with thymic carcinoma.Methods: The subjects of this retrospective study were 18 patients with thymic carcinoma who underwent FDG-PET, before and after induction therapy. We measured the maximum standardized uptake value (SUVmax) of the tumor and analyzed the correlation between the change in SUVmax and pathological response or recurrence.Results: Induction therapy led to a reduction in both the tumor size and SUVmax in most patients. A strong correlation (Pearson coefficient = 0.90, p < 0.0001) was observed between the changes in tumor size and SUVmax. Although the SUVmax and tumor size showed no association with the pathological response, an SUVmax change > 50% predicted lower recurrence rates (p = 0.03).Conclusion: Changes in the SUVmax following induction therapy may serve as a valuable predictor of recurrence in patients with thymic carcinoma. This finding highlights the potential of FDG-PET as a tool for patient monitoring and prognostication of this rare subset of carcinomas. Further studies are warranted to validate these results and standardize the FDG-PET protocols for optimal clinical use.","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00595-024-02954-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To investigate the role of ¹⁸F-fluorodeoxy glucose-positron emission tomography/computed tomography (FDG-PET/CT) to assess pathological response and prognosis after induction therapy in patients with thymic carcinoma.

Methods: The subjects of this retrospective study were 18 patients with thymic carcinoma who underwent FDG-PET, before and after induction therapy. We measured the maximum standardized uptake value (SUVmax) of the tumor and analyzed the correlation between the change in SUVmax and pathological response or recurrence.

Results: Induction therapy led to a reduction in both the tumor size and SUVmax in most patients. A strong correlation (Pearson coefficient = 0.90, p < 0.0001) was observed between the changes in tumor size and SUVmax. Although the SUVmax and tumor size showed no association with the pathological response, an SUVmax change > 50% predicted lower recurrence rates (p = 0.03).

Conclusion: Changes in the SUVmax following induction therapy may serve as a valuable predictor of recurrence in patients with thymic carcinoma. This finding highlights the potential of FDG-PET as a tool for patient monitoring and prognostication of this rare subset of carcinomas. Further studies are warranted to validate these results and standardize the FDG-PET protocols for optimal clinical use.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

诱导治疗后连续正电子发射断层扫描作为胸腺癌患者预后结果的预测因子。

目的：探讨18f -氟脱氧葡萄糖-正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）在胸腺癌诱导治疗后病理反应及预后评价中的作用。方法：回顾性研究18例胸腺癌患者，在诱导治疗前后行FDG-PET检查。我们测量了肿瘤的最大标准化摄取值（SUVmax），并分析了SUVmax变化与病理反应或复发的相关性。结果：诱导治疗使大多数患者的肿瘤大小和SUVmax均减小。相关性强(Pearson系数= 0.90，p 50%预测复发率较低（p = 0.03）。结论：诱导治疗后SUVmax的变化可能是胸腺癌患者复发的一个有价值的预测指标。这一发现突出了FDG-PET作为患者监测和预测这一罕见癌症亚群的工具的潜力。需要进一步的研究来验证这些结果，并使FDG-PET方案标准化，以获得最佳的临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Surgery Today 医学-外科

CiteScore

4.90

自引率

4.00%

发文量

208

审稿时长

1 months

期刊介绍： Surgery Today is the official journal of the Japan Surgical Society. The main purpose of the journal is to provide a place for the publication of high-quality papers documenting recent advances and new developments in all fields of surgery, both clinical and experimental. The journal welcomes original papers, review articles, and short communications, as well as short technical reports("How to do it"). The "How to do it" section will includes short articles on methods or techniques recommended for practical surgery. Papers submitted to the journal are reviewed by an international editorial board. Field of interest: All fields of surgery.